Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.52 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.35 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | NNMT | P40261 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18168201 | 0.98 | NOTUM (0.50) | NOTUMPARP10PARP11DRD2DRD4 | |
| SCHEMBL30047871 | 0.88 | GRIA1 (0.40) | NOTUMBCHEHTT | |
| SCHEMBL20112728 | 0.88 | GRIA1 (0.40) | NOTUMBCHEHTT | |
| SCHEMBL18510121 | 0.79 | NOTUM (0.42) | NOTUMPARP10PARP11NNMTDRD1 | |
| SCHEMBL31702541 | 0.75 | NOTUM (0.42) | NOTUMDRD2DRD4NNMTBCHE | |
| Hydrochloric Acid SCHEMBL31756309 | 0.73 | NOTUM (0.41) | NOTUMDRD2DRD4ACHEDRD1 | |
| SCHEMBL31749685 | 0.73 | PARP10 (0.54) | PARP10PARP11ACHEHTTPTK2B | |
| SCHEMBL10150102 | 0.71 | NOTUM (0.47) | NOTUMPARP10PARP11NNMTDRD1 | |
| SCHEMBL16784815 | 0.71 | CD44 (0.44) | — | |
| SCHEMBL24773047 | 0.71 | NOTUM (0.39) | NOTUMPARP10PARP11DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3800186-B1 | CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER | MISSION THERAPEUTICS LTD (GB) | 2024-10-02 | — | — | EP | disclosed |
| US-11319287-B2 | Cyanopyrrolidines as dub inhibitors for the treatment of cancer | MISSION THERAPEUTICS LIMITED (GB) | 2022-05-03 | — | — | US | disclosed |
| WO-2022073469-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI) , INC. (CN) | 2022-04-14 | — | — | WO | disclosed |
| EP-3800186-A1 | CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER | Mission Therapeutics Limited (GB) | 2021-04-07 | — | — | EP | disclosed |
| US-20200231542-A1 | CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER | MISSION THERAPEUTICS LIMITED (GB) | 2020-07-23 | — | — | US | disclosed |
| US-10669234-B2 | Cyanopyrrolidines as dub inhibitors for the treatment of cancer | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-02 | — | — | US | disclosed |
| EP-3322702-B1 | CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER | MISSION THERAPEUTICS LTD (GB) | 2019-11-20 | — | — | EP | disclosed |
| EP-3137469-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2019-10-09 | — | — | EP | disclosed |
| EP-3137469-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2019-10-09 | — | — | EP | disclosed |
| US-20180194724-A1 | CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER | MISSION THERAPEUTICS LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| US-20160311774-A1 | FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-10-27 | — | — | US | disclosed |
| EP-2870139-B1 | NOVEL ADAMANTYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | HOFFMANN LA ROCHE (CH) | 2016-06-15 | — | — | EP | disclosed |
| WO-2015166366-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2015-11-05 | — | — | WO | disclosed |
| US-9090615-B2 | Adamantyl derivatives as cannabinoid receptor 2 agonists | HOFFMANN-LA ROCHE INC. (US) | 2015-07-28 | — | — | US | disclosed |
| EP-2870139-A1 | NOVEL ADAMANTYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | F. Hoffmann-La Roche AG (CH) | 2015-05-13 | — | — | EP | disclosed |
| US-20150111886-A1 | NOVEL ADAMANTYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2015-04-23 | — | — | US | disclosed |
| CN-104395290-A | Novel adamantyl derivatives as cannabinoid receptor 2 agonists | HOFFMANN LA ROCHE | 2015-03-04 | — | — | CN | disclosed |
| WO-2014005968-A1 | NOVEL ADAMANTYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-01-09 | — | — | WO | disclosed |
| US-20040235867-A1 | Tyrosine kinase inhibitors | BILODEAU MARK T (US) | 2004-11-25 | — | — | US | disclosed |
| WO-2003009852-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669234-B2 | Cyanopyrrolidines as dub inhibitors for the treatment of cancer | USP30, USP39, UCHL1 | NOTUM 1849/4885PARP10 462/4885PARP11 929/4885 |
| US-20150111886-A1 | NOVEL ADAMANTYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | CNR1, CNR2, GPR18 | NOTUM 1466/4885PARP10 1442/4885PARP11 720/4885 |
| US-20180194724-A1 | CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER | USP30, USP39, UCHL1 | NOTUM 1849/4885PARP10 462/4885PARP11 929/4885 |
| US-20160311774-A1 | FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | IDH1, IDH3A, IDH3B | NOTUM 2947/4885PARP10 1523/4885PARP11 828/4885 |
| US-20200231542-A1 | CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER | USP30, USP39, UCHL1 | NOTUM 1849/4885PARP10 462/4885PARP11 929/4885 |
| US-11319287-B2 | Cyanopyrrolidines as dub inhibitors for the treatment of cancer | USP30, USP39, UCHL1 | NOTUM 1849/4885PARP10 462/4885PARP11 929/4885 |
| US-20040235867-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | NOTUM 4556/4885PARP10 2498/4885PARP11 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.